In human cohorts, CYGB expression levels inversely correlate with the progression of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and HCC, highlighting its potential as a clinical biomarker. This evidence concerns the gene CYGB and metabolic dysfunction-associated steatohepatitis.